Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Similar to the second quarter, much of this gross margin improvement was the result of our patient recruitment efforts and, to a lesser extent, continued improvements in utilization rates across the organization |
| We are targeting full year 2024 adjusted gross margins of 40% or more as we continue to realize efficiencies on the patient recruitment front, the value from our technology investments and increases in utilization rates delivering a higher gross profit with continued leverage on SG&A |
| We were particularly pleased with our adjusted gross margin for the fourth quarter |
| Focusing on the investments we’ve made in patient recruitment in particular, we’ve been able to significantly accelerate enrollment rates, which has helped us to drive revenue and customer satisfaction |
| We are pleased with the financial results of the third quarter, and we look forward to a strong end of the year from our commercial team |
| We’ve been able to do this by aligning our patient recruitment sources with our customer contracts, gaining more from our existing community of patients and providers, and significantly improving our patient conversion rates through ongoing process improvement |
| This reflects margin expansion relative to historical results and previous expectations |
| With continued progress on RFP volume and a growing qualified sales pipeline that was more than 33% higher for the fourth quarter than it was for the third quarter, we expect continued bookings and revenue growth in 2024 with a similar approach to expense and cash management |
| I am pleased to report another quarter of solid revenues with significant progress on profitability and cash management on our path to EBITDA positive and cash flow breakeven by the end of 2024 |
| Over this period, we’ve been able to reduce our cost basis which we define as the difference between revenue and adjusted EBITDA by more than 50% |
| So, we are super pleased about it |
| And so that foreshadow is a good future for us in terms of bookings growth, which ultimately will have an improvement in revenue as we increase throughout 2024 |
| Compared to the second quarter, third quarter revenue remained relatively constant as expected, while we achieved significantly higher adjusted gross margins above 40%, gross profit growth of 10%, and adjusted EBITDA improvement of more than 30%, and at the same time, cut cash burn in half |
| In summary, we are encouraged by our third quarter 2023 results and remain optimistic as we continue towards the path to profitability |
| GAAP net loss of $23.5 million in the third quarter a year ago which represents almost a 29% improvement year-over-year |
| Maybe first up on the gross margins, obviously, congratulations, very strong improvement there, both year-on-year and sequentially |
| What’s more is that our cost per patient recruited is 75% lower than it was in the first quarter, a big part of the reason for our gross margin improvement, which is at its highest level since going public |
| Similar to last year, we expect a much stronger fourth quarter as a result |
| And we have been consistent in our communication that we expect to exit fourth quarter of 2024, EBITDA positive with ample cash on hand without having to raise additional capital |
| This is our best quarterly adjusted EBITDA performance since becoming a public company 2 years ago |
| It’s driven by our additional technology improvements that we have been able to make, and it’s driven by our increased utilization rates that we have been able to achieve as well |
| We expect that to continue to have momentum for us |
| While we will provide initial 2024 guidance, when we report the fourth quarter 2023 earnings, given our backlog visibility, our continued progression on RFP volume, and our growing quarterly qualified phased sales pipeline, which is more than 33% higher for the fourth quarter than it was at the same point in the third quarter, we do expect revenue growth in 2024 |
| Thanks for the questions today and appreciate another good quarter |
| We just became members of the Society for Clinical Research Sites, I think which is a testament to the direction that we have gone and the acceptance of this model as being something a bit different from a traditional clinical trial site, but can offer speed and access to patients that no other site can actually provide, which makes us a great complement to a traditional site network |
| As David mentioned, third quarter gross bookings were $17.9 million, which was $6 million or 51% higher than the same period of the prior year |
| The adjusted net loss for the third quarter was $5.4 million, compared to an adjusted net loss of $19.5 million in the same period last year, which represents a 72% improvement over the prior year |
| So, that gives us some increased level of visibility as we look to close out Q4 strong and up from a bookings perspective |
| Adjusted EBITDA, which we calculate by adding back depreciation, amortization, taxes, interest, other income, stock-based compensation and other non-cash charges was a loss of $5.2 million in the third quarter, representing $9.4 million or 64% improvement compared to the same period of the prior year and a $2.3 million or 30.9% sequential improvement compared to the second quarter |
| In regards to the sentiment behind it, we have definitely had sponsor/customer conversations that have circled back to that guidance and reference the fact that it’s there, which gives them confidence to be able to execute a Metasite with them with confidence |
| Statement |
|---|
| Third quarter revenues were $14.9 million, which was $1.3 million or 8% lower than the same period of the prior year and $0.3 million or 3% lower than the second quarter |
| Gross bookings for the third quarter were $17.9 million, which was up more than 50% versus the prior year, but down more than 50% from the previous quarter, a result of similar seasonality trends we’ve seen in prior years in addition to continued delays in decision-making |
| Among other things, this continues to be a result of our market capitalization, which was less than book and book value and cash for a sustained period of time |
| As we close out the year, we expect that our third quarter bookings delays will have a modest impact on our 2023 revenue and we’re now expected to achieve between $58 million and $59 million for the year |
| This was down $7.5 million or more than 39% compared to the same period last year and down $1.4 million or approximately 11% sequentially |
| And then secondly, David, you talked about seasonality, and I understand that, but the drop in the sequential looks a little bit bigger than I would have expected |
| We do expect some higher than higher pass-through expenses in the fourth quarter, which is going to have a little bit of a dip from the 40.8% that we were able to recognize in the third quarter |
| Mike Zaranek And as David said earlier in the prepared remarks, the level of projects on the watch list has decreased |
| But when you are starting to talk about larger deals like we are participating in today, it does have that net effect of some times delays in the decision making |
| GAAP net loss basis, third quarter represented a $13.9 million loss versus a U.S |
| We are adjusting our previous 2023 EBITDA guidance from a loss of $35 million to a loss of $32.5 million |
| Anything else you kind of mentioned delays in decision-making |
| Obviously, pharma, the industry doesn’t move on a dime, but now we are a couple of quarters removed |
| In other words, we effectively cut our cash burn in half on a sequential basis |
Please consider a small donation if you think this website provides you with relevant information